“They are reacting to early evidence suggesting that Omicron is spreading faster than its predecessor, Delta, and is more likely to infect people who were vaccinated or had COVID in the past.”As Omicron Threat Grows, Countries Shorten Wait Time For Covid Booster
https://www.ndtv.com/world-news/omic...ooster-2661333
Forget science, follow the fear
wtf
Badly written. Vaccinated can get it, but not more likely to get it than unvaccinated.“They are reacting to early evidence suggesting that Omicron is spreading faster than its predecessor, Delta, and is more likely to infect people who were vaccinated or had COVID in the past.”
wtf
Try to keep upteh Clintons
It didn't do me any favors.
with all the deflections?
SpFN
https://www.dvidshub.net/news/411320...pment-strategyA series of recently published preclinical study results show that the e Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Ins ute of Research (WRAIR) not only elicits a potent immune response but may also provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.
Scientists in WRAIR’s Emerging Infectious Diseases Branch (EIDB) developed the SpFN nanoparticle vaccine, based on a ferritin platform, as part of a forward-thinking “pan-SARS” strategy that aims to address the current pandemic and acts as a first line of defense against variants of concern and similar viruses that could emerge in the future.
“The accelerating emergence of human coronaviruses throughout the past two decades and the rise of SARS-CoV-2 variants, including most recently Omicron, underscore the continued need for next-generation preemptive vaccines that confer broad protection against coronavirus diseases,” said Dr. Kayvon Modjarrad, Director of the Emerging Infectious Diseases Branch at WRAIR, co-inventor of the vaccine and the U.S. Army lead for SpFN. “Our strategy has been to develop a ‘pan-coronavirus’ vaccine technology that could potentially offer safe, effective and durable protection against multiple coronavirus strains and species.”
Pre-clinical studies published today in Science Translational Medicine indicate that the SpFN vaccine protects non-human primates from disease caused by the original strain of SARS-CoV-2 and induces highly-potent and broadly-neutralizing antibody responses against major SARS-CoV-2 variants of concern including the SARS-CoV-1 virus that emerged in 2002.
SpFN entered Phase 1 human trials in April 2021. Early analyses, expected to conclude this month, will provide insights into whether SpFN’s potency and breadth, as demonstrated in preclinical trials, will carry over into humans. The data will also allow researchers to compare SpFN’s immune profile to that of other COVID-19 vaccines already authorized for emergency use.
“This vaccine stands out in the COVID-19 vaccine landscape,” Modjarrad said. “The repe ive and ordered display of the coronavirus e protein on a multi-faced nanoparticle may stimulate immunity in such a way as to translate into significantly broader protection.”
A Common Risk Factor For Alzheimer’s Disease
May Predispose Carriers To Severe COVID-19
https://scienceblog.com/527487/a-com...evere-covid-19
Experts warn a new COVID pill could backfire and 'crea​te breeding ground for mutant viruses'
the potential drawbacks of molnupiravir, including the frightening possibility that it could—in the words of one researcher—"create a breeding ground for mutant viruses," thereby prolonging the pandemic and adding to its grisly death toll.
"The problem with molnupiravir lies in its mechanism of action,"
"Unlike any previous antiviral drug, molnupiravir does only one thing: It introduces mutations into the viral genome."
molnupiravir relies on inducing even more mutations so that eventually the virus' proteins are damaged beyond function.
while molnupiravir works to some extent, it has not worked very well in Covid-19 patients,"
Merck's pill has proven far less effective in preventing hospitalization than Pfizer's,
"As long as molnupiravir is in use somewhere in the world,
it could generate repeated cycles of new variants,
with people desperately taking the drug to fight the new variants it spawns,
creating a vicious positive feedback loop while causing more suffering and deaths...
The FDA and Merck have essentially engaged the public in a gamble without public debate."
https://www.alternet.org/2021/12/merick-pill/
Yeah, that Merck pill
Congrats to Texas Children's Hospital, the Center for Vaccine Development, and the National School for Tropical Medicine at Baylor College of Medicine.
A cheap scalable vaccine that doesn't require an elaborate cold chain is still needed to tamp down disease and help prevent the emergence of new variants.
https://www.texaschildrens.org/texas...ures-emergencyHOUSTON, TX (December 28, 2021) – Texas Children’s Hospital and Baylor College of Medicine announced today that CORBEVAX™, a protein sub-unit COVID-19 Vaccine, whose technology was created and engineered at its Center for Vaccine Development (CVD), has received Emergency Use Authorization (EUA) approval from the Drugs Controller General of India (DCGI) to launch in India with other underserved countries to follow.
Dubbed “The World’s COVID-19 Vaccine”, it uses a traditional recombinant protein-based technology that will enable its production at large scales making it widely accessible to inoculate the global population. The initial construct and production process of the vaccine antigen was developed at Texas Children’s Hospital CVD, led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).
CORBEVAX™ after completing two Phase III clinical trials involving more than 3000 subjects was found to be safe, well tolerated and immunogenic:
- CORBEVAX™ demonstrated superior immune response in comparison with COVISHIELDTM vaccine when assessed for Neutralizing Antibody (nAb) Geometric Mean ers (GMT) against the Ancestral-Wuhan strain and the globally dominant Delta variant. CORBEVAX™vaccination also generated significant Th1 skewed cellular immune response.
- CORBEVAX™ nAb GMT against Ancestral-Wuhan strain is indicative of vaccine effectiveness of >90% for prevention of symptomatic infections based on the Correlates of Protection assessment performed during Moderna and Astra-Zeneca vaccine Phase III studies.
- CORBEVAX™ nAb GMT against the Delta strain indicates a vaccine effectiveness of >80 percent for the prevention of symptomatic infections based on published studies.
- While none of the subjects who took CORBEVAX™ or COVISHIELD™ had serious adverse events, CORBEVAX™ had 50 percent fewer adverse events than COVISHIELDT™.
- In the continuous monitoring of phase II studies, CORBEVAX™ showed high persistence of immune response as indicated by <30% drop in nAb GMT till 6 months second dose as compared to >80% drop observed with majority of the vaccines.
“Protein-based vaccines have been widely used to prevent many other diseases, have proven safety records, and use economies of scale to achieve low-cost scalability across the world,” said Dr. Maria Elena Bottazzi, Professor and Associate Dean of the National School of Tropical Medicine at Baylor and Co-Director of the Texas Children’s Hospital Center for Vaccine Development. “Our decade-long studies advancing coronavirus vaccine prototypes has led to the creation of this vaccine, which will fill the access gap created by the more expensive, newer vaccine technologies and that today are still not able to be quickly scaled for global production.”
The need for safe, streamlined, low-cost vaccines for middle- to low-income countries is central to the world’s fight against the COVID-19 pandemic. Without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries.
“This announcement is an important first step in vaccinating the world and halting the pandemic. Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant,” said Dr. Peter Hotez, Professor and Dean of the National School of Tropical Medicine at Baylor and Co-Director of the Texas Children’s Hospital Center for Vaccine Development.
“Widespread and global vaccination with our Texas Children’s-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow.”
“Over the years, we have worked to make quality vaccines and pharmaceutical products accessible to families around the world. With this as our backdrop, we resolved to develop an affordable and effective COVID-19 vaccine. It has now become a reality,” said Mahima Datla, Managing Director, Biological E. Limited. “We deeply appreciate Texas Children’s Hospital Center for Vaccine Development, Baylor, CEPI, the Bill and Melinda Gates Foundation, and the government of India for their continuous support and cooperation during this journey. The combined efforts & unceasing support demonstrate that we can collectively overcome any challenge”.
Texas Children’s Hospital CVD received philanthropic support for the development of this vaccine from many generous donors across the country, including a significant contribution from The JPB Foundation in May 2020.
Doses of CORBEVAX could end up being as low as $2.50
Also, "no-frills tech transfer"
The central government of India has already ordered 300 million doses. And BioE, the company manufacturing [Corbevax], plans to produce 100 million or more doses per month starting in February. Approximately 150 million doses have already been produced and are ready to roll out. In addition to what the company is supplying to India, BioE plans to deliver more than one billion additional doses to other countries.
What this means is that Corbevax will soon vaccinate more people than vaccine doses donated so far by the U.S. government or any other G7 country.https://www.scientificamerican.com/a...ccine-for-all/Corbevax is made using technology that has been employed worldwide for decades, meaning that manufacturing processes are generally already well-known and won’t require a steep learning curve like the one needed for the scale-up of new technologies such as mRNA, adenovirus and protein particle vaccines.
When compared with doses of the AstraZeneca–University of Oxford vaccine manufactured by the Serum Ins ute of India, CORBEVAX also produced a higher amount of neutralizing antibodies against the Delta and Beta variants of SARS-CoV-2, the virus that causes COVID (We expect to have Omicron data soon.) And it provided more durable and lasting protection. The vaccine neutralized variants of concern in laboratory animal studies and was highly protective in two nonhuman primate challenge trials.
As a recombinant protein vaccine developed from the receptor biding domain of the e protein on the virus’s surface, combined with Dynavax Technologies’ CpG 1018 adjuvant with alum, the Texas Children’s CVD COVID vaccine can be stored using simple refrigeration. And like the hepa is B vaccine, this COVID vaccine has one of the lowest costs of any available to date. No patents have been filed on the vaccine technology, and Texas Children’s CVD is assisting and co-developing the vaccine alongside BE and other vaccine producers in the Global South, which helps keep the cost low.
20 minute mark
tldw
They are not impressed
Last edited by SnakeBoy; 01-01-2022 at 02:02 PM.
Walmart on Bandera got 16 doses of paxlovid, 10 left.
You need a prescription, no?
the supercollider decision was during Clinton, but Congress' decision not to finance
Clinton was actually very good Repug president, signing 5 conservative strategic objectives
Twixt hammering that chubby Polish girl like trout meat whilst wife & daughter slept above that Oval Office.
They're out now. Ivermectin is all that's left.
there's no quid pro-quo for open source vaccines, the short term electoral payoff for vaccinating the world and stopping variants was way too low for the powers that be.
Open-Source Vaccines Got More Funding From o’s Vodka Than the Government
Why do you keep pumping the ty Hotez vaccine?
ing Trump s just don't understand.
There are currently 1 users browsing this thread. (0 members and 1 guests)
Posting Permissions
Reply With Quote
